{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:41Z","timestamp":1789398161693,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dementia, termed major neurocognitive disorder in the DSM-5-TR, and substance use disorders (SUD) are major and increasingly overlapping public health concerns in the United States. However, population-level trends examining their combined contribution to mortality remain limited. This study evaluates national mortality trends involving both conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of the CDC WONDER Multiple Cause of Death database (2000\u20132023). Deaths listing both dementia and SUD as underlying or contributing causes were identified using ICD-10 codes. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated using the 2000 U.S. standard population. Trends were analyzed using Joinpoint regression, reporting annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 283,206 deaths were identified. The overall AAMR increased significantly from 0.58 in 2000 to 7.63 in 2023 (AAPC: 13.29%; 95% CI: 10.42\u201316.23; p&lt;0.001).<\/jats:p>\n                    <jats:p>\n                      Sex-stratified analysis showed higher mortality in males (AAMR: 0.87\u21929.61) than females (0.41\u21926.23), although females demonstrated a greater relative increase (AAPC: 14.07% vs 12.55%; both\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                    <jats:p>\n                      By race, non-Hispanic (NH) White individuals had the highest absolute rates (AAMR: 0.60\u21928.57), while NH Black individuals exhibited the highest long-term burden (AAPC: 12.69%;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). Hispanic individuals showed lower rates but consistent increases (AAMR: 0.22\u21923.33;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                    <jats:p>\n                      Age-stratified analysis demonstrated increasing age-adjusted mortality rates among individuals aged 45\u201364 years (0.14\u21920.61;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). Among older adults (\u226565 years), mortality rates initially increased substantially (2.79\u219241.94) through 2020 (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001), then declined sharply, reaching 0.61 in 2023 (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                    <jats:p>\n                      Regionally, the Midwest had the highest mortality (AAMR: 0.58\u219210.8; AAPC: 14.38%;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001), while the Northeast had the lowest rates (0.29\u21924.95;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). All regions showed significant upward trends (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                    <jats:p>\n                      Urbanization analysis revealed increasing mortality in metropolitan (0.56\u21923.5) and non-metropolitan areas (0.71\u21923.8), with stronger growth in non-metropolitan regions (AAPC: 16.72% vs 15.82%;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mortality involving both dementia and substance use disorders has increased substantially in the United States over the past two decades, with significant disparities across sex, race, geography, and urbanization. These findings highlight the growing burdens of neurodegenerative disease and substance use, emphasizing the need for integrated public health strategies targeting both conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05117-8","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:14:54Z","timestamp":1782688494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rising trends in dementia and psychoactive drug-related mortality in the United States, 2000\u20132023. A retrospective analysis using CDC WONDER"],"prefix":"10.1186","volume":"26","author":[{"given":"Unsa","family":"Arif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Moeez","family":"Awais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eraj","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishan","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Wassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheer Bin","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falak","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanhia","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Touseef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modibo","family":"Yattassaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"5117_CR1","unstructured":"World Health Organization. Dementia. Geneva: World Health Organization. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Cited 2026 14 Feb."},{"issue":"5","key":"5117_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455\u2013532.","journal-title":"Lancet Neurol"},{"key":"5117_CR3","doi-asserted-by":"crossref","unstructured":"2025 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2025;21(4):e70235.","DOI":"10.1002\/alz.70235"},{"issue":"6","key":"5117_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/jamaneurol.2022.0976","volume":"79","author":"RA Nianogo","year":"2022","unstructured":"Nianogo RA, Rosenwohl-Mack A, Yaffe K, Carrasco A, Hoffmann CM, Barnes DE. Risk factors associated with Alzheimer disease and related dementias by sex and race and ethnicity in the US. JAMA Neurol. 2022;79(6):584\u201392.","journal-title":"JAMA Neurol"},{"issue":"8","key":"5117_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S1474-4422(14)70154-1","volume":"13","author":"GJ Biessels","year":"2014","unstructured":"Biessels GJ. Capitalising on modifiable risk factors for Alzheimer\u2019s disease. Lancet Neurol. 2014;13(8):752\u20133.","journal-title":"Lancet Neurol"},{"key":"5117_CR6","unstructured":"American Addiction Centers. Alcohol and drug abuse statistics (facts about addiction). Brentwood (TN): American Addiction Centers. Cited 2026 14 Feb."},{"key":"5117_CR7","unstructured":"National Center for Drug Abuse Statistics. Substance abuse and addiction statistics. Cited 2026 14 Feb."},{"issue":"2","key":"5117_CR8","first-page":"4","volume":"5","author":"TJ Gould","year":"2010","unstructured":"Gould TJ. Addiction and cognition. Addict Sci Clin Pract. 2010;5(2):4\u201314.","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"5117_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/dar.12922","volume":"38","author":"CJWH Bruijnen","year":"2019","unstructured":"Bruijnen CJWH, Dijkstra BAG, Walvoort SJW, Markus W, VanDerNagel JEL, Kessels RPC, et al. Prevalence of cognitive impairment in patients with substance use disorder. Drug Alcohol Rev. 2019;38(4):435\u201342.","journal-title":"Drug Alcohol Rev"},{"key":"5117_CR10","doi-asserted-by":"publisher","first-page":"1526270","DOI":"10.3389\/fphar.2025.1526270","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, Hao Y, Ma D, Feng L, Yang F, An P, et al. Neurotoxicity mechanisms and clinical implications of six common recreational drugs. Front Pharmacol. 2025;16:1526270.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5117_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0453-0","volume":"11","author":"J Rehm","year":"2019","unstructured":"Rehm J, Hasan OSM, Black SE, Shield KD, Schwarzinger M. Alcohol use and dementia: a systematic scoping review. Alzheimers Res Ther. 2019;11(1):1.","journal-title":"Alzheimers Res Ther"},{"key":"5117_CR12","doi-asserted-by":"publisher","first-page":"1165262","DOI":"10.3389\/fpsyt.2023.1165262","volume":"14","author":"MP Aranda","year":"2023","unstructured":"Aranda MP, Liang J, Wang X, Schneider LS, Chui HC. The relationship of history of psychiatric and substance use disorders on risk of dementia among racial and ethnic groups in the United States. Front Psychiatry. 2023;14:1165262.","journal-title":"Front Psychiatry"},{"issue":"2","key":"5117_CR13","doi-asserted-by":"publisher","first-page":"e030969","DOI":"10.1161\/JAHA.123.030969","volume":"13","author":"AMK Minhas","year":"2024","unstructured":"Minhas AMK, Kewcharoen J, Hall ME, Warraich HJ, Greene SJ, Shapiro MD, et al. Temporal trends in substance use and cardiovascular disease\u2013related mortality in the United States. J Am Heart Assoc. 2024;13(2):e030969.","journal-title":"J Am Heart Assoc"},{"key":"5117_CR14","unstructured":"Centers for Disease Control and Prevention. Multiple cause of death, 1999\u20132020 request. Atlanta (GA): CDC. Cited 2026 14 Feb."},{"key":"5117_CR15","unstructured":"Centers for Disease Control and Prevention. ICD-10-CM classification of diseases. Atlanta (GA): CDC. Cited 2026 14 Feb."},{"key":"5117_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133738","author":"A Alqasem","year":"2025","unstructured":"Alqasem A, AlAmmari A, Alhajji M, Alzahrani A, Aljohani A, Alharbi A, et al. Trends in heart failure-related mortality among psychoactive drug users in the United States: a nationwide cross-sectional analysis of the CDC WONDER database. Int J Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133738.","journal-title":"Int J Cardiol"},{"issue":"3","key":"5117_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/neurosci7030066","volume":"7","author":"H Ali","year":"2025","unstructured":"Ali H, Shahid I, Ahmed A, Khan M, Fatima S, et al. National trends and demographic disparities in mortality involving co-recorded Parkinson\u2019s disease and dementia in the United States, 1999\u20132025: a CDC WONDER analysis. NeuroSci. 2025;7(3):66. https:\/\/doi.org\/10.3390\/neurosci7030066.","journal-title":"NeuroSci"},{"key":"5117_CR18","unstructured":"STROBE Initiative. STROBE statement. Cited 2026 14 Feb."},{"key":"5117_CR19","unstructured":"National Center for Health Statistics. 2013 NCHS fina urban-rural classification scheme for counties. Hyattsville (MD): NCHS. Cited 2026 14 Feb."},{"key":"5117_CR20","unstructured":"National Center for Health Statistics. Geographic division or region \u2013 Health, United States. 2024. Cited 2026 14 Feb."},{"key":"5117_CR21","volume-title":"Age standardization of death rates: implementation of the year 2000 standard [Internet]","author":"RN Anderson","year":"1998","unstructured":"Anderson RN, Rosenberg HM. Age standardization of death rates: implementation of the year 2000 standard. Hyattsville (MD): National Center for Health Statistics. 1998."},{"key":"5117_CR22","unstructured":"National Cancer Institute. Joinpoint regression program. Cited 2026 14 Feb."},{"key":"5117_CR23","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text rev. Washington (DC): American Psychiatric Association Publishing. 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"5117_CR24","doi-asserted-by":"publisher","first-page":"g5205","DOI":"10.1136\/bmj.g5205","volume":"349","author":"S Billioti de Gage","year":"2014","unstructured":"Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer\u2019s disease. BMJ. 2014;349:g5205.","journal-title":"BMJ"},{"key":"5117_CR25","doi-asserted-by":"publisher","first-page":"e6231","DOI":"10.1136\/bmj.e6231","volume":"345","author":"S Billioti de Gage","year":"2012","unstructured":"Billioti de Gage S, B\u00e9gaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population-based study. BMJ. 2012;345:e6231.","journal-title":"BMJ"},{"issue":"10248","key":"5117_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care. Lancet. 2020;396(10248):413\u201346.","journal-title":"Lancet"},{"issue":"11","key":"5117_CR27","first-page":"e1913845","volume":"2","author":"BH Han","year":"2019","unstructured":"Han BH, Moore AA, Sherman S, et al. Demographic trends of binge alcohol use. JAMA Netw Open. 2019;2(11):e1913845.","journal-title":"JAMA Netw Open"},{"key":"5117_CR28","doi-asserted-by":"crossref","unstructured":"Weich S, Pearce HL, Croft P et al. Effect of anxiolytic drugs on mortality. BMJ. 2014;348:g1996.","DOI":"10.1136\/bmj.g1996"},{"issue":"2","key":"5117_CR29","first-page":"315","volume":"22","author":"A Bianchetti","year":"2021","unstructured":"Bianchetti A, Rozzini R, Boffelli S, et al. Psychotropic drug use and mortality in dementia patients. J Am Med Dir Assoc. 2021;22(2):315\u201321.","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"5117_CR30","first-page":"635","volume":"41","author":"M Defrancesco","year":"2021","unstructured":"Defrancesco M, Marksteiner J, Fleischhacker WW, et al. Use of benzodiazepines in Alzheimer\u2019s disease. J Clin Psychopharmacol. 2021;41(6):635\u201342.","journal-title":"J Clin Psychopharmacol"},{"key":"5117_CR31","unstructured":"Maldonado JR. Delirium pathophysiology and management. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023."},{"issue":"12","key":"5117_CR32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"L Degenhardt","year":"2018","unstructured":"Degenhardt L, Charlson F, Ferrari A, et al. Global burden attributable to substance use. Lancet Psychiatry. 2018;5(12):987\u20131012.","journal-title":"Lancet Psychiatry"},{"issue":"06","key":"5117_CR33","first-page":"193","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","unstructured":"Centers for Disease Control and Prevention. Alcohol-attributable deaths\u2014United States. MMWR Morb Mortal Wkly Rep. 2003;52(06):193\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5117_CR34","unstructured":"Hedegaard H, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States. NCHS Data Brief. 2024;(522)."},{"issue":"2","key":"5117_CR35","doi-asserted-by":"publisher","first-page":"e180217","DOI":"10.1001\/jamanetworkopen.2018.0217","volume":"1","author":"T Gomes","year":"2018","unstructured":"Gomes T, Tadrous M, Mamdani MM, et al. Opioid-related mortality trends. JAMA Netw Open. 2018;1(2):e180217.","journal-title":"JAMA Netw Open"},{"issue":"43","key":"5117_CR36","first-page":"1487","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. Vital signs: opioid overdoses. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487\u201392.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5117_CR37","volume-title":"The impact of the COVID-19 pandemic on noncommunicable disease resources and services","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. The impact of the COVID-19 pandemic on noncommunicable disease resources and services. Geneva: WHO; 2020."},{"key":"5117_CR38","volume-title":"Sex differences in substance use","author":"National Institute on Drug Abuse","year":"2020","unstructured":"National Institute on Drug Abuse. Sex differences in substance use. Bethesda (MD): NIDA; 2020."},{"issue":"1","key":"5117_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0453-0","volume":"11","author":"J Rehm","year":"2019","unstructured":"Rehm J, Hasan OSM, Black SE, et al. Alcohol use and dementia: systematic review. Alzheimers Res Ther. 2019;11(1):1.","journal-title":"Alzheimers Res Ther"},{"key":"5117_CR40","doi-asserted-by":"publisher","first-page":"j2353","DOI":"10.1136\/bmj.j2353","volume":"357","author":"A Topiwala","year":"2017","unstructured":"Topiwala A, Allan CL, Valkanova V, et al. Moderate alcohol consumption and brain outcomes. BMJ. 2017;357:j2353.","journal-title":"BMJ"},{"issue":"11","key":"5117_CR41","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jama.289.11.1405","volume":"289","author":"KJ Mukamal","year":"2003","unstructured":"Mukamal KJ, Kuller LH, Fitzpatrick AL, et al. Alcohol consumption and dementia. JAMA. 2003;289(11):1405\u201313.","journal-title":"JAMA"},{"issue":"10113","key":"5117_CR42","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"G Livingston","year":"2017","unstructured":"Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention and care. Lancet. 2017;390(10113):2673\u2013734.","journal-title":"Lancet"},{"issue":"2","key":"5117_CR43","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols E, Steinmetz JD, Vollset SE, et al. Global prevalence of dementia. Lancet Public Health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"issue":"2","key":"5117_CR44","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Global dementia burden. Lancet Public Health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"issue":"10200","key":"5117_CR45","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","volume":"394","author":"J Rehm","year":"2019","unstructured":"Rehm J, Shield KD. Alcohol use disorders burden. Lancet. 2019;394(10200):781\u201392.","journal-title":"Lancet"},{"issue":"7","key":"5117_CR46","first-page":"613","volume":"388","author":"ND Volkow","year":"2023","unstructured":"Volkow ND, Blanco C. Substance use disorders. N Engl J Med. 2023;388(7):613\u201327.","journal-title":"N Engl J Med"},{"key":"5117_CR47","volume-title":"National healthcare quality and disparities report","author":"Agency for Healthcare Research and Quality","year":"2021","unstructured":"Agency for Healthcare Research and Quality. National healthcare quality and disparities report. Rockville (MD): AHRQ; 2021."},{"issue":"9904","key":"5117_CR48","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","volume":"382","author":"HA Whiteford","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of mental disorders. Lancet. 2013;382(9904):1575\u201386.","journal-title":"Lancet"},{"key":"5117_CR49","unstructured":"Spencer MR, Warner M, Bastian BA et al. Drug overdose deaths. NCHS Data Brief. 2022;(457)."},{"issue":"1","key":"5117_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/alzrt157","volume":"5","author":"NJ Ridley","year":"2013","unstructured":"Ridley NJ, Draper B, Withall A. Alcohol-related dementia. Alzheimers Res Ther. 2013;5(1):3.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"5117_CR51","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1360-0443.2010.03351.x","volume":"106","author":"JM Boden","year":"2011","unstructured":"Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011;106(5):906\u201314.","journal-title":"Addiction"},{"key":"5117_CR52","unstructured":"Chen LH, Hedegaard H, Warner M. Drug poisoning deaths. NCHS Data Brief. 2014;(133)."},{"issue":"1","key":"5117_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1192\/bjp.bp.108.055335","volume":"195","author":"EL Sampson","year":"2009","unstructured":"Sampson EL, Blanchard MR, Jones L, et al. Dementia in acute hospitals. Br J Psychiatry. 2009;195(1):61\u20136.","journal-title":"Br J Psychiatry"},{"key":"5117_CR54","unstructured":"Vespa J, Medina L, Armstrong DM. Demographic turning points. Curr Popul Rep. 2020;P25\u20131144."},{"issue":"2","key":"5117_CR55","first-page":"171","volume":"165","author":"S Galea","year":"2007","unstructured":"Galea S, Ahern J, Tracy M, et al. Neighborhood income and health. Am J Epidemiol. 2007;165(2):171\u20139.","journal-title":"Am J Epidemiol"},{"issue":"10334","key":"5117_CR56","first-page":"1223","volume":"399","author":"GBD 2021 Risk Factors Collaborators","year":"2022","unstructured":"GBD 2021 Risk Factors Collaborators. Global risk factors burden. Lancet. 2022;399(10334):1223\u201349.","journal-title":"Lancet"},{"issue":"10258","key":"5117_CR57","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"CJL Murray","year":"2020","unstructured":"Murray CJL, Aravkin AY, Zheng P, et al. Global burden of disease. Lancet. 2020;396(10258):1223\u201349.","journal-title":"Lancet"},{"issue":"2","key":"5117_CR58","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.amepre.2013.10.017","volume":"46","author":"GK Singh","year":"2014","unstructured":"Singh GK, Siahpush M. Rural\u2013urban disparities. Am J Prev Med. 2014;46(2):e19\u201329.","journal-title":"Am J Prev Med"},{"issue":"2","key":"5117_CR59","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1377\/hlthaff.21.2.60","volume":"21","author":"NE Adler","year":"2002","unstructured":"Adler NE, Newman K. Socioeconomic disparities. Health Aff. 2002;21(2):60\u201376.","journal-title":"Health Aff"},{"key":"5117_CR60","doi-asserted-by":"publisher","first-page":"173495","DOI":"10.1016\/j.pbb.2022.173495","volume":"221","author":"C Delcher","year":"2022","unstructured":"Delcher C, Harris DR, Anthony N, Stoops WW, Thompson K, Quesinberry D. Substance use disorders and social determinants of health from EMRs. Pharmacol Biochem Behav. 2022;221:173495.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"5117_CR61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1377\/hlthaff.2015.0917","volume":"35","author":"BD Sommers","year":"2016","unstructured":"Sommers BD, Blendon RJ, Orav EJ, et al. Healthcare utilization after Medicaid expansion. Health Aff. 2016;35(1):181\u20139.","journal-title":"Health Aff"},{"issue":"7","key":"5117_CR62","doi-asserted-by":"publisher","first-page":"e883","DOI":"10.1016\/S2214-109X(19)30172-X","volume":"7","author":"KE Sleeman","year":"2019","unstructured":"Sleeman KE, de Brito M, Etkind S, et al. Global burden of serious health-related suffering. Lancet Glob Health. 2019;7(7):e883\u201392.","journal-title":"Lancet Glob Health"},{"key":"5117_CR63","volume-title":"SUDORS fatal overdose data","author":"Centers for Disease Control and Prevention","year":"2023","unstructured":"Centers for Disease Control and Prevention. SUDORS fatal overdose data. Atlanta (GA): CDC; 2023."},{"issue":"4","key":"5117_CR64","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMra1511480","volume":"374","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, Koob GF, McLellan AT. Neurobiology of addiction. N Engl J Med. 2016;374(4):363\u201371.","journal-title":"N Engl J Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05117-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05117-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05117-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:04:03Z","timestamp":1789394643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05117-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5117"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05117-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. The research is based on de-identified data and does not require the consent of the participants or ethics approval.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"580"}}